Hims & Hers Stock: Performance Analysis and Market Insights
Hims & Hers Health, Inc. (NYSE: HIMS) is a brand quickly gaining notoriety in the telehealth and wellness industry. The company is best known for providing healthcare services via the Internet by connecting users with licensed providers in the United States, the United Kingdom, and other international markets. Hims stock & Hers provides a variety of products, including prescription and over-the-counter wellness goods and personal care products.
In just the last few years, Hims stock & Hers has turned heads with consumers and investors alike due to its rapid rise in revenue, customer growth, and expansion into new health categories. However, like any growth story, the stock features ample opportunities, but it must also be watched for risk.
In this blog, we will take a look at what the company does, what the stock is doing, some significant industry developments, and opportunities and risks that investors should consider in the clearest and simplest way possible.
What Hims & Hers Does
Hims & Hers runs an online platform where customers can get healthcare advice, prescriptions, and wellness products without visiting a clinic. Through its websites and mobile app, the company offers:
- Prescription and Non-Prescription Products: Customers can purchase medicines, supplements, skincare, etc. as a one-time purchase or subscription.
- Healthcare Services: Licensed providers will provide consultations, ongoing treatment plans, and post-care support.
Speciality Categories:
- Wellness: Products such as melatonin (for sleep) and biotin (for hair/nails).
- Skin Care: Moisturisers, creams, sunscreens, serums, oils, and cleansers.
- Sexual Health: Condoms, lubricants, vibrators, climax delay sprays, and wipes.
- Hair Care: Shampoos, conditioners, scalp scrubs, topical treatments (minoxidil).
In addition to selling directly to customers, Hims & Hers also sells their products to wholesale partners. Hims & Hers is headquartered in San Francisco, California.
Stock Overview
- Ticker: HIMS
- Exchange: NYSE
- Recent Price: ~$51.94 (August 2025)
- Market Cap: About $11.7 billion
- 52-Week Range: $13.47 – $72.98
- P/E Ratio: ~57.6
- EPS: $0.79
Over the past year, the stock has been very volatile. It has more than doubled year-to-date, but it has also seen sharp pullbacks after earnings reports. This kind of movement shows both investor excitement and nervousness about the company’s future growth.
Recent Financial Performance
Q2 2025 Earnings – Highlights
- Revenue: $544.8 million (up 73% year-over-year), but slightly shy of analyst estimates of $552 million.
- Earnings per Share (EPS): Adjusted EPS of $0.17-$0.19, exceeding estimates of $0.15.
- Subscribers: Up 31% to 2.4 million.
- Multi-Condition Plans: Up 170% to approximately 500,000 customers.
Revenue was strong but the slight miss on revenue was impactful as the share price fell about 12-14% in after-hours trading when these results were released.
Growth Drivers
A. Expansion into New Health Segments
The company started with hair loss and erectile dysfunction treatments but has since moved into:
- Weight-loss medications (including GLP-1 drugs like semaglutide during shortage periods).
- Mental health services such as therapy and psychiatry.
- Menopause and hormone treatments.
- At-home lab testing for broader health checks.
B. International Growth
Hims acquired Zava, a European telehealth provider, to expand its reach beyond the U.S. This move opens up new markets and revenue streams.
C. Subscription Model
Recurring revenue from subscribers gives Hims & Hers predictable income and helps retain customers for longer periods.
Challenges and Risks
A.Regulatory Changes
The FDA has changed the regulations of compounded GLP-1 weight-loss drugs. Hims has benefitted from selling these drugs during different times of shortages, and new regulations might put constraints on the sales of the drugs.
B.Reliance on Weight-Loss Trends
Weight-loss treatments have driven revenue for Hims, but it presents a risk of dependence on one part of the business. If the demand slows down or competing options enter the arena, it may affect growth potential.
C.High Valuation
A P/E (price to earnings) ratio over 50 means the market is anticipating growth of Hims. If in the near or distant future things don’t play out well for Hims & Hers that disappoints earnings, there is a high risk that the stock will free-fall.
D.Corporate Governance Issues
According to ISS (Institutional Shareholder Services), the Governance QualityScore is rated as the following:
- Audit: 2 (low risk)
- Board: 8 (higher risk)
- Shareholder Rights: 10 (highest risk)
- Compensation: 10 (highest risk)
A score of 10 on the QualityScore indicates higher governance risk compared to peer companies.
Market Sentiment
Analysts have mixed views on Hims & Hers:
- Average Rating: Hold
- Average Price Target: Around $38.30 (suggesting a downside from current levels).
Some analysts believe the long-term growth story is intact, while others worry about near-term volatility and regulation changes.
Competitors
Hims & Hers competes with companies in healthcare, personal care, and wellness. Related tickers include:
- ELF – e.l.f. Beauty
- HNST – The Honest Company
- EL – Estée Lauder
- PG – Procter & Gamble
- UL – Unilever
While these aren’t pure telehealth companies, they compete in overlapping product categories like skincare and personal care.
Upcoming Events
- Next Earnings Date: November 4, 2025
Investors will closely watch whether Hims & Hers can meet or beat revenue expectations and show continued subscriber growth.
Pros and Cons for Investors
| Pros | Cons |
| Strong revenue growth (up 73% YoY in Q2 2025) | Recent revenue miss caused sharp stock drop |
| Expanding into multiple healthcare categories | High valuation may limit upside |
| Growing subscriber base and recurring revenue model | Regulatory risks around key drug products |
| International expansion via Zava acquisition | Governance concerns with high ISS risk scores |
| Diversification beyond initial men’s health focus | Stock volatility makes short-term investing risky |
Conclusion
Hims & Hers Health has established a good presence in the telehealth market by providing convenient, discreet, and affordable options for health-delivery services. Its transition from a narrow focus on men’s health to a broader wellness platform allowed it to build a large subscriber base and generate billions in revenue.
For the investors in the group, the larger concerns are:
- Can the company maintain the same momentum with its subscriber numbers?
- Will the gains in new healthcare categories offset any declines in weight-loss drug sales?
- Can management navigate the shifting regulatory conditions as well as disruptions related to governance?
If you view yourself as a long-term investor who believes in telehealth and wellness growth, Hims & Hers is worth following especially if the stock gets cheaper. However, if you prefer stable, steady stocks with lower volatility, this might be seen as too risky for your portfolio.
FAQs
Q1: What does Hims & Hers Health do?
They operate an online telehealth application to provide health and wellness consults and offer products in multiple categories including skincare, hair care, sexual health and wellness, and weight loss.
Q2: What is Hims & Hers stock performance like in 2025?
The stock is up significantly year-to-date, but is volatile, and has traded between $13.47 and $72.98 in the past 12 months.
Q3: What were the highlights of the Q2 2025 earnings?
Revenue grew 73% to $544.8M Q2 earnings, topped EPS expectations and subscriber growth was strong. For reference, revenue was slightly below analyst expectations.
Q4: What risks should investors consider?
The risks to be aware of include possible changes to regulation on compounded weight-loss drugs, high relative valuation that factors in future growth potential, and governance-related risks.
Q5: Is Hims & Hers stock a good investment?
Perhaps for long-term investors who plan to hold and expect continued expansion of telehealth, but perhaps not for risk averse or conservative investors.